Colorectal Cancer

The patients with chest or colorectal cancer, two of the most common cancers of the world, can wait advances more add of the treatment with Avastin (r) (bevacizumab) and Herceptin (r) (trastuzumab) after the new data that are being presented in 44th American society of the clinical annual meeting of the oncologia (LOATHING) in Chicago in the May end. Around 30,000 medical specialists will attend the meeting that is the first event for the therapy of the cancer in the entire world.

The data of Roche will show that Avastin and Herceptin are continuing to offer a additional hope to improve the survival in the patients with cancers that still are devastando thousand of lives every year.

Cancer of the breast

- Avastin: Late-breaking given of phase III of the AVADO it studies Avastin of inquiry in combination with docetaxel (docetaxel, equally known as Taxotere, is the one of the quimioterapias more than general use for the cancer of the breast) will detach the encouraging effectiveness and the results of the security in the patients had local dealt with first-line for the cancer the periodic or metasttico breast of negative HER-2.

- Herceptin: The new results that use the therapy Herceptin-based for patients with cancer of aggressive positive breast HER-2 will be disclosed equally. The data of study GBG26 will be centered on the importance of the treatment continued with the Herceptin in the women with cancer of the advanced metasttico breast whose the illness progressed in a Herceptin-base therapy.

- Pertuzumab: The very promising data of phase II will be presented in pertuzumab of inquiry of the drug that will detach the benefits that pertuzumab in combination with Herceptin could offer to the patients with cancer of the advanced breast. Pertuzumab is the first one of a new, innovative classroom of whitened agents known as ITS inhibitors of dimerisation that they can inhibit the growth of the cancerous cell finally and leading to the death of the cancerous cells

Colorectal cancer

- Avastin: The first presentation of the data of the therapy Avastin-based with or without cetuximab (one drug that attacks the cancer differently the Avastin) in the patients with metasttico colorectal cancer will be shared.

- Avastin: In the long run impressive the total data of the survival in two years, involving one 4,000 patients dealt with the Avastin first-line in combination with a variety to regimes of the chemotherapy will confirm the essential paper that Avastin is playing now in the patients with advanced colorectal cancer. The results of the studies are significant because on 50 percent of the peoples diagnosised with colorectal cancer dies currently of the illness and these data show that the improvements in the survival are realizable. (1)

Roche will almost present 300 summaries and posters in LOATHING that advances in other main cancers demonstrate, as well as the described data already above in the chest and colorectal. With one of the most detailed plumbings of the research and the development of the oncologia in the industry, Roche is being strengthenn to still more deliver options of the treatment in the fight of meeting to the cancer. For example, the program of the clinical assay of Avastin includes 40,000 patients in the entire world.

The full details of the presentations of data keys of Roche will be available in friday 30o May in an event of ways it invitation-only for the journalistas no-E.U. All the summaries are available in: http://www.asco.org/ASCO/Meetings.

Notes

- The cancer of the breast is one of the most common types of cancer in the women, the eight nine percent of the women will develop this cancer during its lifetime.(1) every year more than a million of new examples of the cancer of the breast is diagnosised (2) with a tax of mortality on of 500.000 peoples per the year. (3)

- Avastin fold the possibility of a patient who lives without its advance of the illness (of the free progression survival). When used in combination with taxanes (chemotherapy), Avastin substantially increases the effectiveness of the treatment with impact limited in the security. The studies show that this the continuous direct inhibition of VEGF with Avastin maximizes the benefit of the treatment for the patient.

- Herceptin is a projected humanizado antibody specifically to whiten and to obstruct the HER2 function, that cause tumors fast-growing, aggressive of the cancer of the breast. Herceptin delivers high taxes of the cure for women with cancer of the breast in advance of positive HER2 and extends to the survival through all the periods of training of the cancer of positive breast HER2 activating the imunitrio system and suppressing HER2. Herceptin is considered the foundation of the care in the women with cancer of the breast of recommended HER2-positive and in directrizes of the treatment in the entire world.

- The Colorectal cancer is the most common cancer in the developed countries (4) and the seconds - the majority of cause of common death of the cancer through all the cancer types inside men and women through Europe. (5)

- Avastin actua obstructing VEGF, mediator key of the angiogenesis of the tumor, offering the patients a better possibility of the survival significantly improved. Avastin is the first inhibitor anti-angiogenic to increase the survival in first and the second line treatment and to supply significant improvements in the time that the patients can live without its advance of the illness.

The annual meeting of 2008 LOATHING occurs May 31 June the 3, place of McCormick, Chicago, Illinois, U.S.A. The full details can be found in http://www.asco.org.

References

1. Wilking N and Jonsson B. A Pan-European comparison regarding the patient access to the cancer drugs. Institute of Karolinska in contribution with the school of the economy, stocolmostocolmo, Sweden, 2005

2. World-wide organization of Sade (WHO) 2003. It sees here.

3. World-wide organization of Health, projections of mortality and load of the illness the 2030

4. Parkin DM. Esteem the load of the cancer of the world: GLOBOCAN 2000. Int. Cancer 2001 of J; (94): 153-156

5. Boyle P, incidence of the cancer of Ferlay J. and mortality in Europe, 2004. Annals of oncologia 2005; 16:481 - 488

http://www.roche.com

The dutch authorities of health said of Vaccinogen Incorporation had permitted it to more manufacture its vaccine of cancer of the anti-dois points of OncoVAX of the discovery, cancelling immediately the passage of the one than USS100 million of vendas europias potentials.

Aprova0 dutch of the easiness of the company based on Emmen, the Netherlands also paves the way its clinical experimentation of IIIb of the pivotal phase it FDA them And U. — the final stage before the vaccine can be vendida in the United States.

“the easiness can produce annually up to 3.500 vaccines, equivalent the USS130 million in the incomes,” said Michael G. Hanna, Jr, Ph.D., CEO of Vaccinogen. “this number only scratches out the surface of the potential demand for a vaccine of cancer of colon of period of training II. One of each three patients who have its to cancer removed to see to return it — and the results is generally fatal.”

“our experience with OncoVAX resulted in for more than increasing the possibility of the patients of survival 50%,” it concliu. “this represents a chance for a new lease in the life for ten of the thousands of the patients around the world.”

The dutch license allows to the company commercialize the vaccine, first in Switzerland and then others in seven countries in Eastern Europe. The vaccine of OncoVAX represents potential a medical discovery because it uses proper stacks of cancer of a patient to hinder that cancer it returns a successful operation after to remove it.

“this license of manufacturing that she is being granted for the the most respected most strict copyholders and of manufacturing of biotech in Europe is main a noticeable landmark for Vaccinogen because it starts to generate incomes of OncoVAX,” Dr. said Hanna. “worldwide of vaccines is also a main pull for the acceptance individualized of cancer.”

On OncoVAX

Immunotherapy of OncoVAX is based on a decade-long attempt for scientists to transform the reply and its memory in the long run of the body immune to hinder the return of the illness years after the surgery. Such approach has been already successful in hindering a number of illnesses infectious.

On Vaccinogen

Vaccinogen is a biopharmaceutical company that develop and commercializes the vaccines of cancer and other products immunotherapeutic — to cancer of turn in Itself(TM). Based in Frederick, MD, the company it has a portfolio of candidates of the product for the treatment of cancer, the illness infectious, illnesses autoimmune, anti-inflammatory and of antibodies monoclonal entirely human in some periods of training of the clinical development.

Vaccinogen

Curis, Incorporation (Nasdaq: CRIS), a company of development of the drug focused in developing the following generation of the whitened medicines proprietors for the treatment of cancer, announced today that its Genentech collaborator initiated a clinical experimentation of GDC-0449 phase II, a verbal-managed small antagonist of Hedgehog of the molecule, in colorectal cancer metastatic. In consequence, Genentech will make a money payment $3 million the Curis under the agreement companies ‘ of the contribution of June 2003.

“we are hopeful that GDC-0449 can one day supply to an option additional to the existing standard of the colorectal care patients metastatic of cancer,” we said president of Curis and CEO Dan Passeri. “beyond, Genentech has announced previously that planeia to initiate two clinical experimentations of additional phase II of GDC-0449 to as half of 2008, including experimentations in the advanced basal carcinoma of the stack, where the patient answers had been observed in the phase where ongoing I study, and in an advanced continuous tumor undisclosed of the epithelial origin. We look at onward to supply ones updates more we add in these programs in the future.”

GDC-0449 will be evaluated in approximately 150 patients with cancer colorectal metastatic in combination with the current standard of the care in an experimentation randomized, placebo-controlled, double-blind of phase II. The patients will receive chemotherapy from FOLFOX or FOLFIRI in combination with bevacizumab and randomized to receive GDC-0449 or placebo. They will be stratified based in regimen of chemotherapy chosen and if or them criteria of the evaluation of the reply in the continuous illness measurable of tumors (RECIST) are not current in the base line. RECIST supplies to the parameters standard to be used when registering the patient reply tumors continuous. The preliminary objective of the progression-free experimentation is survival of randomization to the progression or the death of the illness. The secondary measures of the result include the measure of the expression of the protein of Hedgehog in the fabric archival and to follow of adverse events. The experimental details are affixed on ClinicalTrials.gov.

Cancer of Colorectal remains a medical necessity of unmet main, with the American society of cancer that esteem that approximately 150,000 new cases and 50,000 deaths will be attributable to this cancer in the United States in 2008. Cancer of Colorectal is the second root cause of the death of cancer in the United States and cancer more frequently diagnosised of third.

If GDC-0449 to advance in subsequent periods of training to test physician and of aprova0 regulatory, Curis would be eligible to receive payments adds of the noticeable landmark of the money of Genentech. Beyond, in the event that the candidate of the drug commercialized successfully, Curis is eligible to receive royalties in vendas from the product.

On Curis, Inc..

Curis is a company of development of the drug that is committed leveraging its technologies signaling innovative of the drug of pathway to look for to create new medicines, first to cancer it. In expanding its efforts of the development of the drug in the field of cancer through its whitened platform of the development of the drug of cancer, Curis is building in top of its preceding experiences in whitening pathways signaling for the development of therapies whitened of cancer of the following generation. For more information, Web site of Curis ‘ of the visit in http://www.curis.com.

Cautionary indication

This release of the press will count ahead-to inside look at indications of meaning of the confidential act of the reform of litigation of seguranas of 1995, including without limitation: indications regarding the plants of Genentech to initiate three clinical experimentations of GDC-0449 phase II and the expectations of the company regarding potential the clinical benefits of GDC-0449. Ahead-to look at the used indications in this release of the press it can contain the words “believes”, “it waits”, “it anticipates”, “planeia”, “looks for”, “it esteem”, “”, “the similar expressions can” or. These indications for ahead-looking at are not guarantees of the future performance and they do not involve the important risks, uncertainties, assumptions and other factors that it can among others make with that the real results are materially different of those indicated by such indications ahead-to look at including, things:

- the adverse results, delay and/or the imperfections in the internal programs of development of the product of the company, including without limitation unplanned delay and/or imperfections in the efforts of the company to file a new application investigative of the drug and to advance more plus its candidate of the product, CUDC-101, and the other programs under its whitened platform of the development of the drug of cancer;

- the adverse results, are slow and/or the imperfections in the antagonist of pathway of Hedgehog program currently under the clinical development for the collaborator of the company, Genentech, so that the company cannot not have nenhuns foreknowledge and excess that the company will not have no control;

- the difficulties or are slow in getting or keeping required approvals regulatory for the products that are being become for the company internally and with its contribution with Genentech;

- ability of Curis ‘ to get or to keep the patent and to another protection necessary proprietor of the copyright for the development and commercialization of the products based on its technologies;

- changes inside, or inability of Curis ‘ to execute, its plant of business;

- the risk that the company does not get to finance additional substantial required to lead the research and the development of its candidates of the product;

- requirements and expenditures unplanned of money that, among others things, could shorten the esteem period where the company will have the money to finance its operations and where it could adversely affect the expenditures if also operate esteem of the company for 2008 and beyond;

- risks that become related it the ability of the company to participate in and keeping collaborations strategical important, including its current contribution with Genentech, and the risk that collaborators will not execute adequately;

- pressures competitive; e

- other factors of risk identified in the quarterly report in the form 10-Q for the room had finished September 30, 2007 and other fillings that the company makes peridicamente with commission of seguranas and of exchange.

Beyond, all the indications for ahead-looking at only represent the sights as of today and they do not have to be trusted upon as the representation of the sights as of no subsequent date. Curis contradicts all the intention or obligation to bring up to date some of the indications for after ahead-looking at the date of this release of the press if in consequence of the new information, future events or in another way.

Curis, Inc..

Incisions great, opened that they cause pain and they require successfully patient long times healing could have been unnecessary to deal with colorectal cancer, in accordance with a new revision of the studies.

“for much time, many surgeons had been distrustful that laparoscopy could damage the colorectal survival in patients of cancer and cause metastases in the openings of the skin that are used to introduce the instruments, but this proved not to be the case,” said copyholder Esther Kuhry of the linking, M.D., a general resident of the surgery in the hospital of Namsos in Norway.

Cancer of Colorectal is one of the most common types of cancer in the United States. In accordance with the national institute of cancer, will have 148,810 new disgnostic of colorectal cancer in 2008.

In an goal-analysis that combined the results of 12 experimentations that involve 3,346 patients, the revisory comparative results of the used opened surgeries laparoscopic and in the colorectal treatment of cancer and did not find no difference significant enters the two types of surgeries when it came to the survival and the taxes in the long run of the return of cancer.

Five studies had occurred in the United States; the others had occurred in China, Formosa, in Portugal, in Italy, Spain and the Joined Kingdom.

The revision appears in the the most delayed introduction of the library of Cochrane, a publication of the contribution of Cochrane, an international organization that avale the medical research. The systematic revisions extract conclusions evidence-based on the practical doctor after to have considered the index and the quality of existing medical experimentations in a topic.

In procedures laparoscopic, the surgeon leads the surgery through the small punctures in the abdomen and uses a camera to visualize the indices abdominal of the person. These procedures revolutionized the room operating themselves, leading to incisions lesser, the little pain and the times of a faster recovery for the patients who require the removal of gallbladder, appendectomies, the common shunting line gastric and other surgeries gastrointestinal.

Still, because of a lack of the information on results in the long run of the surgery laparoscopic, the surgeons had trusted traditional the open surgery to the patients of cancer of colon of the delight. In the opened surgery, cut of the surgeons through longer the abdominal wall and of incisions of the use to see directly colon of the patient and to remove the fabric cancerous.

Based in the results of the revision, “the surgery laparoscopic to cancer it of colon he is associated with the taxes of the survival and mortality that they are equal to the opened surgery,” said Kuhry. The revision did not find no difference significant enters the two five year groups in the terms of the metastasis of cancer, taxes short-term and and deaths of the survival caused by cancer.

The copyholders had also evaluated the incidence of the bands of the adhesions of the fabric of the scar that give to form between agencies and fabric and hernias in the place of incision, two common complications after the colorectal surgery of cancer. They had not found no significant difference in the taxes of these complications between the opened groups laparoscopic and of the surgery.

However, to cancer it rectal, not sufficiently evidence is available to extract conclusions approximately reliable if the surgery laparoscopic compares com.segurana with the opened surgery, said Kuhry. Two enclosed studies had only evaluated patients with cancer rectal separate.

“more studies are emerging that they suggest that the approach laparoscopic to resection colorectal of cancer is equivalent in the terms of the control of cancer. However, data more in the long run are needed to verify this and more complete data are required before any one can say that it is better or, “said Janice Rafferty, M.D. preferred, head of the division of colon and the rectal surgery in the university of the college of Cincinnati of the medicine.

Rafferty, that was not involved with the revision, said that it only includes “some studies and the numbers overwhelmingly becomes consequently completely small to be powerful.”

“he is true that it seems that the results laparoscopic in the surgery of cancer are equivalents, but that one is not a strong argument sufficiently to say that it must be offered to all the patients of cancer, that [ the authors ] says in the conclusion,” it said.

The authors do not argue the surgical experience and the curve of necessary learning for resection laparoscopic of cancer of colon, and if or this did not influence resulted, said Rafferty: “although everything, if each abdominal surgeon will be going to hang its hat in these results, has that to have guidelines established on who resection is qualified to make this ‘ equivalent ‘ of cancer.”

Before laparoscopy can extensively be used to treat colorectal cancer, the surgeons must adequately have to train to execute these surgical procedures of colorectal cancer mnima invasive, Kuhry said in an interview. Until recently, the surgeons had executed the surgery mainly laparoscopic for the colorectal treatment of cancer inside of the structure of clinical studies, it had written down.

When he comes to evaluate treatments colorectal of cancer, is vital patient to remember that laparoscopy is one technique, not a science, said Rafferty.

“he is not for each patient,” said. “to the times expeditious to the removal of cancer is in the more better interest of the patient to have a traditional approach, because what is starting lost here it is that the entire patient needs to be considered, not only the size of its incision.”

Kuhry and, et al. Results in the long run of resection colorectal laparoscopic of cancer (database of Review).Cochrane of systematic revisions 2008, edition 2.

The contribution of Cochrane is an organization nonprofit, the independent International that produce and disseminates systematic revisions of interventions of the care of health and promotes the search for the evidence in the form of clinical experimentations and other studies of interventions. Visit http://www.cochrane.org for more information.

ServiceNotcia Of The Behavior Of The Health
Center for the advance of Flowery avenue 2000 of of the health nanowatt, Ste 210
Washington, C.C. 20009
United States
http://www.hbns.org

Poniard Pharmaceuticals, Incorporation (Nasdaq: PARD), a focused biopharmaceutical company in oncology, announced today that chemotherapy of evaluation of the combination finished the patient register in its it picoplatin of the clinical experimentation of phase 2 for the treatment first-line it to cancer colorectal metastatic (CRC). The advanced data of this experimentation half expect it as of 2008. Picoplatin, candidate of the product of the linking of the company, is a new agent of chemotherapy of platinum of the generation with the potential to changed a product of the platform that dirige it multiple indications, the combinations and formulations.

“Picoplatin, to the date, demonstrated tolerability good, with nenhuns neuropathies severe when combined with the 5-fluorouracil and leucovorin in regimen of FOLPI. In our experimentation of phase 2, we are executing a comparison head-to-head of efficacy and the security of picoplatin with oxaliplatin. We will be presenting the preliminary phase 2 data and the phase updated 1 data in the society of 2008 Americans of the clinical annual meeting of oncology (LOATHING), and we anticipate data more physicians this year for presentations in some scientific meetings, “we said RobertJager, M.D., main medical officer of Poniard. “the data of our experimentation ongoing of phase 2 could establish picoplatin as a product of the platform and to supply a continuous foundation to support experimentations you add of the register, expanding in this way the potential of this product.”

Picoplatin is an agent chemotherapeutic that it has an improved profile of comparative security to chemotherapeutics platinum-based existing. He was projected to surpass the resistance of platinum associated with the treatment of tumors continuous. Picoplatin was evaluated in more than 750 patients and demonstrated to the activity anti-tumor in multiple indications with toxicity less severe of kidney (nephrotoxicity) and toxicity of the nerve (neurotoxicity) of that is observed generally with other drugs of chemotherapy of platinum.

Details Of The Study Of Phase 2

The study of phase 2 it is an two-arm, experimentation 100-patient randomized, controlled of the treatment first-line of the CRC metastatic. The objective of the experimentation of phase 2 is to compare the security and efficacy of picoplatin intravenous given a time that each four weeks in regimen of FOLPI with oxaliplatin in combination with fluorouracil 5- and leucovorin in modified regimen FOLFOX-6 and to evaluate the clinical activity. Poniard waits to generate given of the test-$$$-CONCEITO of experimental phase 2 demonstrating that picoplatin has an improved profile of security. This experimentation could locate picoplatin as the preferred agent of platinum for the treatment first-line of colorectal cancer metastatic and could potential allow a study of phase 3.

– inica Poniard the experimentation of phase 2 in November 2007 based in the clinical activity and the promising data of security observed in its 50-patient, phase 1 study of the dose-dose-escalation of picoplatin in regimen of FOLPI as a treatment first-line for the CRC metastatic. The results of the experimentation of phase 1 had been presented in symposium satellite of cancers gastrointestinal of LOATHING in January and had demonstrated that picoplatin has one toxicity manageable in combination with 5-fluorouracil and leucovorin Picoplatin did not cause neurotoxicity severe (raised classroom 3 or more), as are seen generally in the patients metastatic of the CRC dealt with oxaliplatin as the part to regimen of FOLFOX. Guidelines national physicians detailed current of the practical one of the net of cancer (NCCN) in oncology to cancer it of colon three months of the therapy or more soon if neurotoxicity stimulate discontinuation of FOLFOX after significant if to become (greater classroom 3 or). Nephrotoxicities and ototoxicities was rare and soft.

Poniard anticipates to present efficacy and the data of security in scientific meetings, including given preliminary of the phase 2 and data updated of the experimentations of the CRC of phase 1 in LOATHING in June.

On Picoplatin

Picoplatin, candidate of the product of the platform of the linking of the company, is a new therapy of platinum of the generation with improved existing platinum-base therapies relative.to of cancer of the security profile. Picoplatin is projected to surpass the resistance of platinum associated with chemotherapy in tumors continuous, and is being studied in multiple indications, combinations and formulations of cancer. Beyond to the clinical experimentation phase 2 ongoing in the patients with CRC metastatic, Poniard is evaluating picoplatin intravenous in a pivotal experimentation ongoing of phase 3, known as the SPEAR (study of efficacy of Picoplatin after relapse), in SCLC. This experimentation of the register currently is being lead under a special evaluation of the protocol (SPA) of the administration of the food and the drug of United States and is evaluating the total survival as endpoint preliminary. The company is also evaluating picoplatin intravenous in a clinical experimentation of phase 2 ongoing for the treatment of hormone-refractory cancer of prostate. Picoplatin verbal is being evaluated in a clinical experimentation of phase 1 in tumors continuous. Formulation verbal of picoplatin the same has active pharmaceutical ingredient that formulation intravenous. Picoplatin was not approved by no authority regulatory for the use in the human beings.

On PharmaceuticalsPoniard

Poniard Pharmaceuticals, Incorporation is a biopharmaceutical company focused in the development and commercialization of innovative products of oncology to impactar the lives of the peoples with cancer. For the additional information it visits http://www.poniard.com please.

This release will count ahead-to look at indications, including the indications regarding the objectives of business of the company and the strategical objectives, of the plants of development of the drug, the results of clinical experimentations and the potential security and efficacy of its products in the development. The real results of the company can differ materially from those indicated in these based indications for ahead-looking at in a number of factors, including the risks and the uncertainties associates with the activities of the research and the development of the company; the results to test pre- physician and physician; the receipt and synchronism of required approvals regulatory; the acceptance of market of the considered products of the company; the losses operating itself anticipated, necessity for the future capital and ability of the company to get to finance future; competition of the third parties; the ability of the company to preserve and to protect right of copyright; the dependence of the company in manufacturers and suppliers third-party; the lack of the company of vendas and the experience of the marketing; the ability of the company to attract and to hold back the personal key; changes in the technology, the regulation of the government and general conditions of market; e the described risks and uncertainties in the current and periodic reports of the company had filed with commission of seguranas and of exchange (second), including the annual report of the company in the form 10-K per the year had finished December 31, 2007 and quarterly report in the form 10-Q for the finished room March 31, 2008, where it will be filed with as or on May 8, 2008. The readers are warned not to ahead- place reliance improper in these indications for being looked at, that they only speak as of the date of this release. The company does not undertake no obligation to bring up to date no indication for ahead-looking at to reflect the information, events or new circumstances after the date of this release or to reflect the occurrence of events unanticipated.

(c) 2008 PharmaceuticalsPoniard, Incorporation All the all rights reserved.

Poniard and pharmaceuticals of Poniard is the registered marks of pharmaceuticals of Poniard, Inc..

PharmaceuticalsPoniard, Inc..
http://www.poniard.com

The recent work of the center finnish of academy of excellence in the biology of cancer in the university of Helsnquia, Finland, has the light of the source in the mechanisms of the development of the tumor of colon and can help to project the treatment best for this illness.

Cancer of colon he is one of malignancies most common in occidental countries: the men and the women almost face a risk of the life of 6% for the development of colorectal cancer invasive. The studies epidemiologic had shown that diverse factors contribute to the development of this illness, such as the diet of the highly fat one, red-meat, obesity and the lack of vegetables and the fiber in the diet.

In the great majority of the cases, colorectal cancer arises of one overgrowth initially benign of the lining colonic, one polyp adenomatous so-called (Fig. 1), that it acquires with mutations harmful of the time and transforms into a dangerous carcinoma colonic. The studies observational suggest that the sequence of the adenoma–adenoma-to-carcinoma makes examination of up to 10 years. Although the half of the population occidental person almost can shelter polyps adenomatous for the age of 50, they is esteem that only some percent of the adenomas will progress when cancer.

The published study as a publication in advanced line of the stack of cancer, it describes a mechanism why polyps harmless of colon they acquire the ability to give to form tumors malignant. The investigators of the university of Helsnquia had discovered that PROX1, a protein that in the embryos controlled the formation of normal agencies, such as the liver or the eye, if it abnormally becomes overproduced in advanced periods of training of the development of the carcinoma. PROX1 allows that the stacks of the tumor grow uniforms in the absence of signals stimulating to surround weaveeed normal, that leads to overgrowth and the advanced development dangerous of tumors.

The removal of PROX1 of the stacks of cancer inverts its behavior malignant, suggesting that PROX1 is a promising target for the development of the future therapies to cancer it of colon.

The article was adaptou today for Medical Notice of the release of the original press.

The study it was lead by academy of the friend of the research of Finland, the Dr. Tatiana Petrova and the professor of academy, the Dr. Kari Alitalo, that jointly supervised the work of a graduated student of the university Antti NyknenHelsnquia. The research is a result of the contribution between cancer and biologists, pathologists, geneticists and bioinformaticians developmental of Finland, of U.S.A., of France, Joined Kingdom and Austria.

The research in the laboratories of the Dr. Tatiana Petrova and the Dr. Kari Alitalo is supported by the foundation of Sigrid Juslius, for the association for the research of cancer international, for academy of Finland and the organizations finnish of cancer.

Source: Kari Alitalo
University of Helsnquia

It has a number of investigators that are procurarando for useful markers of the tumor to indicate the cure. The antigens are being applied as an efficient target in the clinical therapy. Hb3 is one antibody monoclonal of produced anti-colorectal cancer in the laboratory of the investigators, and whose sensitivity and specificity is superior to that one of anti-CEA. The preceding results had shown that CA-Hb3 can be useful in the clinical diagnosis of colorectal cancer.

This study, carried through for a team lead for professor G. C. Li, he is described in an article of the research that is published March in 14, 2008, in the periodical of the world of gastroenterology.

To identify detailed proteins of the antigen Ca-Hb3 tumor-associate who is recognized for antibody monoclonal Hb3 of the colorectal carcinoma, Ca-Hb3 was isolated for SDS-PAGE followed for the digestion with trypsin. Peptides of trypsin had been analyzed by spectrometry massive chromatography-in liquid tandem (LC-MS/MS). Applying bioinformatics to analyze the proteins that had been identified by spectrometry massive, Ca-Hb3 was identified as the protein of CKAP4-similar for the analysis in tandem of spectrometry massive of Nano-Nano-HPLC. The molecular weight of the CKAP4-similar protein is kDa 62,02, including a region hydrophobic, the one domain of transmembrane, five reeled bobbins, four places of glycosylation and places of phosphorylation of forty-sing to sleep it. The CKAP4-similar protein has the homogeneity raised with Np63A, and the characteristic expression of the alpha agrNp63 that oncogene potential in isoforms of p63 is considered one is similar the Ca-Hb3.

Np63A is one isoform of the family p63. A number of studies oncogenic of the alpha of agrNp63 had detached the potential alpha.agrNp63 is overexpressed in diverse cancers epithelial, frequent in consequence of amplification of the gene. Overexpression of one isoform of Np63A in stacks of 1A of the rat increases the growth of the colony in the soft formation of the tumor of the agar and xenograft in rats nude. Hypothesized that the alpha agrNp63 promotes the survival and the maintenance of the capacity proliferative in stacks of epithelial connecting rod and stacks of cancer.

The article was adaptou today for Medical Notice of the release of the original press.

Reference: Sun S, Guo FJ, Tong YQ, Zhu JG, GC Of Li.
Research on colorectal carcinoma the associated antigen Ca-Hb3 for the one-dimensional PAGE and spectrometry massive chromatography-in liquid tandem.
World J Gastroenterol 2008; 14(10): 1588-1591 http://www.wjgnet.com/1007-9327/14/1588.asp

Correspondence: I read of Guam-Cheng, professor, institute of research of cancer, school of Xiangya of the medicine, central south university, road of 110 Xiangya, Changsha 410078, province of Hunan, China.

On the periodical of the world of gastroenterology

The periodical of the world of gastroenterology (WJG), main an international periodical in gastroenterology and hepatology, had established a reputation for the first research publishing of the classroom on esophageal cancer, cancer gastric, cancer of the liver, the hepatitis viral, colorectal cancer, and of pylori of H infection to supply to a forum physicians and scientists. WJG was located and abstracted in the current medicine of Contents/Clinical, the index of the citation of expanded science (also known as SciSearch) and in the edition of the Reports/Science citation of the periodical, in the Medicus index, the MEDLINE and the chemical PubMed, summaries, EMBASE/Excerpta Medica, periodicals of summaries, gastroenterology physician and Hepatology of the practical one of the nature, summaries of the TAXI and global health. ISI JCR 2003-2000 IF: 3.318. 2,532, 1,445 and 0.993. WJG is a weekly periodical published by the WJG press. The dates of the publication are 7o, 1, 21o, and 28o day of each month. The WJG is supported by the national natural foundation of the science of China, no. 30224801 and no. 30424812, and was established with the name of the national periodical of China of gastroenterology new October in 1, 1995, and rebaptized WJG January in 25, 1998.

On the Press of WJG

The WJG press mainly publishes the periodical of the world of gastroenterology.

Source: Jing Zhu
Periodical of the world of gastroenterology

The analysis of LOH in the sporadical carcinoma by means of the markers of the microsatellite changedded a way efficient to find regions allelic of the deletion and to find then genes of the suppresor of the tumor of the candidate. In a preceding study, one met that D1S413 (1q31.1-32.1, 9.8cM) showed higher frequencies of LOH, that they indicated that the region could shelter gene(s) putative of the suppresor of the tumor. However, the region allelic of the deletion contained thus many genes that was inconvenient to continue the election of the gene and the functional study. Consequently, a additional exploration of LOH with the markers high-density of the microsatellite in the region is found to be necessary to narrow the space of the research and to select few genes of the candidate in the finite regions for the functional research.

This study, executed for the Dr. Chong-Zhi Zhou and its colleagues, he is described in an article of the research to be published March in 14, 2008, in the periodical of the world of gastroenterology.

They had analyzed to trace fine of LOH of 1q31.1-32.1 and had inside found a minimum region of the frequent deletion been situated of a segment 2-M genomic in D1S413-D1S2622 in 1q31.3-32.1.

Then procurarando in the databases, they had presumed that CSRP1 could be the carcinoma-related gene colorectal of the candidate in this region.

In the opinion the authors, the changes genetic in the carcinogenesis colorectal are not understood entirely. However, the LOH analysis is an efficient method to find loci informative and subsequently to identify genes of the suppresor of the tumor of the candidate.

This study it found the region suppressed critical and it needs in 1q31.1-32.1 and since that given significant to help to disclose the mechanisms of the carcinogenesis colorectal.

One searches additional must carry through the microarray-base election of the gene of the highone and must include the research functional to find the gene potential of the suppresor of the tumor.

The article was adaptou today for Medical Notice of the release of the original press.

Reference: Zhou CZ, Qiu GQ, Fan JW, Wang Xl, Spike HM, Huang L, Sun YH, Peng ZH.
To trace fine of the loss of heterzygosity in 1q31.1-32.1 in the sporadical colorectal carcinoma.
World J Gastroenterol 2008; 14(10): 1582 http://www.wjgnet.com/1007-9327/14/1582.asp

Correspondence: Dr. Zhi-Hai Peng, department of the general surgery, hospital of the first person affiliated of the university of Shanghai Jiaotong, road of 85 Wujin, Shanghai 200080, China.

On the periodical of the world of gastroenterology

The periodical of the world of gastroenterology (WJG), main an international periodical in gastroenterology and hepatology, had established a reputation for the first research publishing of the classroom on esophageal cancer, cancer gastric, cancer of the liver, the hepatitis viral, colorectal cancer, and of pylori of H infection to supply to a forum physicians and scientists. WJG was located and abstracted in the current medicine of Contents/Clinical, the index of the citation of expanded science (also known as SciSearch) and in the edition of the Reports/Science citation of the periodical, in the Medicus index, the MEDLINE and the chemical PubMed, summaries, EMBASE/Excerpta Medica, periodicals of summaries, gastroenterology physician and Hepatology of the practical one of the nature, summaries of the TAXI and global health. ISI JCR 2003-2000 IF: 3.318. 2,532, 1,445 and 0.993. WJG is a weekly periodical published by the WJG press. The dates of the publication are 7o, 1, 21o, and 28o day of each month. The WJG is supported by the national natural foundation of the science of China, no. 30224801 and no. 30424812, and was established with the name of the national periodical of China of gastroenterology new October in 1, 1995, and rebaptized WJG January in 25, 1998.

On the Press of WJG

The WJG press mainly publishes the periodical of the world of gastroenterology.

Source: Jing Zhu
Periodical of the world of gastroenterology

It has significant discrepancies in recollection of black women to have had elections of the health — including tests to cancer it of the chest, the cervical one and of colon — and its medical registers, in accordance with a published small study in the forum of the cares of oncology of the periodical, reports of the health of Reuters. The black color more have raised taxes of death of the one than white of cancer of the chest, the cervical one and of colon, and the investigators attribute disparity in the part to lower taxes of the election, that reduces the possibility of the advanced detection, reports of the health of Reuters.

For the study, the investigator Barbara Powe of the linking and the colleagues had interviewed 116 black women on its history of the election of the health and had compared its answers with its medical registers. The investigators had found discrepancies between the medical answers of the women and its registers in a majority of the cases. Based in comparisons of the answers and real the medical registers of the women, the investigators had found that one:

• 86% of the women age 20 or older told to have one they exam clinical of the chest in some point in its lives, and 67% told to have had one in last the 12 months, compared with 35% and 26%, respectively, based in medical registers;
• 77% of the women in its 40s told to have one mammogram in some point in its life, and 29% told to have had one in last the 12 months, compared with 40% and indicated 9% in medical registers;
• 56% of ages 50 or older of the told women to submit it a test of fecal blood occult to detect cancer of colon, when the medical registers had indicated 11% had a FOBT; e
• Almost all the women had interviewed told to have had a test of Pap in some point in its lives, compared with 58% of the medical registers.

The investigators had said that it is possible that in some cases the elections had not been told in medical registers. The estimates of taxes of the election of cancer first are based on the self-report, in accordance with the health of Reuters. Findings of the study suggests that the current election evaluates, particularly for black women, is probably lower of the one than esteem. Powe said in an indication, “Self-it told taxes of the election is the foundation for many decisions of politics that have a significant influence in the availability of the resources for this population,” adding that “exceeding or underestimation of the election can exactly be more significant for [ black ], that loads one burden disproportionate of cancer.” The investigators had recommended that the suppliers more better develop “patient systems of the reminder” to help close the a opening to the discrepancy (health of Reuters, 4/28).

Reprinted with amiable permission of http://www.kaisernetwork.org. You can see daily the report entire of the politics of health of Kaiser, procurarar the archives, or sign them above for the delivery of the email in http://www.kaisernetwork.org/dailyreports/healthpolicy. The daily report of the politics of health of Kaiser is published for kaisernetwork.org, a free service of the foundation of J. Kaiser Family of the Henry.

the association Kingdom Join-based for the research that of cancer international this week announced it will finance a project of the university of Griffith lead for Dr. Joe Tiralongo to develop more plus a treatment to anti-cancer potential that it shows resulted promising in laboratory tests.

The concession will allow the team to test a new composite scale ‘ of the designer ‘ in tumours in alive stacks.

It searches the Dr. Joe Tiralongo of the leader of the institute of Griffith for Glycomics, Queensland said that the composites whiten an original sugar, acid sialic, believed to give the stacks of cancer its mortal ability to spread through the body.

“a significant number of the studies showed a consistent linking enters the amount of acid sialic of the sugar in the surface of stacks of cancer, and the ability of this cancer to metastasise, or spread to other parts of the body,” it said.

Acid sialic is found in the stacks during all the body, giving, for the example, saliva its characteristic viscosity, but it is expressed abnormally in stacks of cancer.

“it exists in much more great numbers in the surface of stacks of cancer. You the stacks of cancer that they are leagued all to other stacks during the body, “Dr. said Tiralongo could almost describe it as ‘ a glue ‘ these aids.

“we are working to sew ‘ an inhibitor ‘ that obstructs the mechanism that allows stacks of cancer to express this sugar in its surface.”

“if the progression can be delayed and cancer to be contained to a portion of the body, becomes much more easy to deal with the surgery.”

It said when cancer of colon it was the preliminary target, the team would also select of meeting to others cancers inhibiting aggressive, including cancer of chest and neuroblastoma.

“these cancers all on-express acid sialic, thus in the theory that works cancer could work for another one.

Cancer of colon she is one of the most dangerous types of cancer and of the most common cause of as of the death of cancer, with one in 18 men australian and one in 26 affected women.

The patients of the reports of the advice of the national health australian and medical research with cancer of colon located they have ones 88 % of survival possibility, however this leaves to fall only the seven percent when cancer spread other agencies.

The association for the scientific mark international Matfield of the Dr. of the coordinator of the research of cancer said hindering that tumours spreads would be a new way to treat cancer controlling.

“it is the ability of cancer to spread around the body that makes fatal it,” it had said.

“it would not cure it but, in the majority of cases that would make one unnecessary cure because one tumour non-spreading would not be a significant problem of health.”

The article was adaptou today for Medical Notice of the release of the original press.

AICR, the association for the research of cancer international, have financed some of the more better scientific research in the world per almost 30 years. It supports the basic research for promising and prominent scientists to improve the prevention, the detection and the treatment of the illness.

Source: Jeannette Langan
Australia research